2019: PhD in "Molecular Medicine" at the Medical University of Graz
2019-2021: PostDoc at the Ludwig Boltzmann Institute for Lung Vascular Research
2021-2024: Division of Physiology and Pathophysiology, Otto Loewi Research Center, MedUniGraz
2024-now: Otto Loewi Research Center, Lung Research Cluster, MedUniGraz
Research Interest: pathomechanisms of pulmonary circulation and chronic lung diseases; molecular mechanisms of disturbed endothelial-immune cell crosstalk in the development chronic lung diseases.
Publication highlights:
- Birnhuber et al., Eur Respir J 2019: showed how IL-1 can dampen collagen production of pulmonary mesenchymal cells and balances pro-fibrotic actions of the immune system.
- Birnhuber et al., Resp Research 2020: indicated an increase of pulmonary fibrosis and inflammation in the bleomycin-induced lung fibrosis model following administration of CDK4/6 inhibitor Palbociclib
- Birnhuber et al., Eur Respir J 2022: highlighted how pirfenidone worsens pulmonary function in the Fra-2 TG SSc-ILD model due to its negative effects on endothelial cells primed by type 2 inflammation.
- Birnhuber et al., Am J Physiol Lung Cell Mol Physiol 2025: demonstrated that pulmonary hypertension in the Fra-2 TG mouse model is multifactorial, conjointly elicited by type inflammation, increased vasoconstriction and progressive pulmonary arterial remodeling
2019: PhD in "Molecular Medicine" at the Medical University of Graz
2019-2021: PostDoc at the Ludwig Boltzmann Institute for Lung Vascular Research
2021-2024: Division of Physiology and Pathophysiology, Otto Loewi Research Center, MedUniGraz
2024-now: Otto Loewi Research Center, Lung Research Cluster, MedUniGraz
Research Interest: pathomechanisms of pulmonary circulation and chronic lung diseases; molecular mechanisms of disturbed endothelial-immune cell crosstalk in the development chronic lung diseases.
Publication highlights:
- Birnhuber et al., Eur Respir J 2019: showed how IL-1 can dampen collagen production of pulmonary mesenchymal cells and balances pro-fibrotic actions of the immune system.
- Birnhuber et al., Resp Research 2020: indicated an increase of pulmonary fibrosis and inflammation in the bleomycin-induced lung fibrosis model following administration of CDK4/6 inhibitor Palbociclib
- Birnhuber et al., Eur Respir J 2022: highlighted how pirfenidone worsens pulmonary function in the Fra-2 TG SSc-ILD model due to its negative effects on endothelial cells primed by type 2 inflammation.
- Birnhuber et al., Am J Physiol Lung Cell Mol Physiol 2025: demonstrated that pulmonary hypertension in the Fra-2 TG mouse model is multifactorial, conjointly elicited by type inflammation, increased vasoconstriction and progressive pulmonary arterial remodeling